Closing GTOP (Genitope) underperform
Another wildly successful biotech underperform. And I've still got a few coming down the pike - see FVRL, ACEL, TELK, etc. If only it was this easy to call the winners. In regards to the CEO trying to put a shine on a turrrd with his post-results discussion, that optimistic crapola about subsets analysis and highly significant results is pure boilerplate you'll see in every press release after every phase III trail failure. Don't expect Genitope to rebound any time soon.